2023
Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer
Pasquini L, Morris M. Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer. 2023, 387-405. DOI: 10.1007/978-3-031-39005-0_19.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerRadium-223Radiopharmaceutical therapyTreatment of metastatic castration-resistant prostate cancerMinimal bone marrow toxicityRadium-223 dichlorideVisceral metastatic diseaseBone marrow toxicityNearby cancer cellsBone painMarrow toxicityMetastatic diseaseOverall survivalCombination therapyMetastatic spreadBone involvementAlpha therapyClinical developmentTreatment strategiesPalliative effectCancer cellsCancerBoneOptimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters
Shariftabrizi A, Kothari S, George S, Attwood K, Levine E, Lamonica D. Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters. The Oncologist 2023, 28: 246-251. PMID: 36651837, PMCID: PMC10020806, DOI: 10.1093/oncolo/oyac245.Peer-Reviewed Original ResearchConceptsBaseline BSIBone scan indexMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerOverall survivalSkeletal metastasesRa-223 therapyRa-223 treatmentRadium-223 treatmentTreatment-associated reductionChemotherapy-naïve patientsMedian overall survivalAbsolute neutrophil countRadium-223 dichlorideHigh serum PSANovel treatment modalitiesAlkaline phosphatase levelsChemotherapy-naïveTreatment tolerabilityNeutrophil countSerum PSABone scanLaboratory parametersPatient selection
2020
Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial.
Morris M, Fong L, Petrylak D, Sartor A, Higano C, Pagliaro L, Alva A, Appleman L, Tan W, Vaishampayan U, Porcu R, Tayama D, Kadel E, Yuen K, Datye A, Armstrong A. Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L metastatic castration-resistant prostate cancer (mCRPC): Results from a phase Ib clinical trial. Journal Of Clinical Oncology 2020, 38: 5565-5565. DOI: 10.1200/jco.2020.38.15_suppl.5565.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerPSA response ratePSA progressionDosing schedulesPD-L1Clinical benefitResponse ratePD-1/PD-L1Castration-resistant prostate cancerPhase Ib clinical trialPhase 1b studyPhase Ib studyTumor-directed radiationAnti-tumor immunityDose-limiting toxicityRadium-223 dichlorideLimited treatment optionsMechanism of actionEvaluable ptsRadiographic PFSMCRPC patientsMedian OSBaseline characteristicsEvaluable dataUnacceptable toxicity
2019
870P A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Petrylak D, Vaishampayan U, Patel K, Higano C, Albany C, Dawson N, Mehlhaff B, Quinn D, Nordquist L, Wagner V, Shen J, Trandafir L, Sartor O. 870P A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Annals Of Oncology 2019, 30: v340-v341. DOI: 10.1093/annonc/mdz248.027.Peer-Reviewed Original ResearchBone health agentsSSE-free survivalSymptomatic skeletal eventsMetastatic castration-resistant prostate cancerMedian overall survivalOverall survivalWeek 24Primary endpointBayer HealthCare PharmaceuticalsRa-223Open-label phase 2a studyTreatment-emergent adverse eventsBayer PharmaceuticalsCastration-resistant prostate cancerSeattle GeneticsPhase 2a studyPhase IIa studyRadium-223 dichlorideSmall study populationBristol-Myers SquibbALSYMPCA studyECOG 0/1Prior therapySecondary endpointsTreatment discontinuation
2015
Stochastic simulation of radium-223 dichloride therapy at the sub-cellular level
Gholami Y, Zhu X, Fulton R, Meikle S, El-Fakhri G, Kuncic Z. Stochastic simulation of radium-223 dichloride therapy at the sub-cellular level. Physics In Medicine And Biology 2015, 60: 6087-6096. PMID: 26216391, DOI: 10.1088/0031-9155/60/15/6087.Peer-Reviewed Original ResearchConceptsEstimate radiation damageAlpha particle tracksAlpha-particle emittersMonte Carlo modelIonization clustersDose depositionAlpha particlesAlpha emissionParticle therapyAlpha-particle therapyEnergy depositionRadiation damageCarlo modelEfficacy of cell killingParticle emittersRadium-223 dichlorideBone-seeking radionuclidesParticle trackingRadium-223Prostate cancerAverage doseCell nucleiCell killingIndirect DNA damageNucleus
2014
A randomized open-label phase 2a study evaluating the efficacy and safety of radium-223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases.
Petrylak D, Rosenberg J, Garosi V, Siegel J, Goldin J. A randomized open-label phase 2a study evaluating the efficacy and safety of radium-223 dichloride (Ra-223) in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Journal Of Clinical Oncology 2014, 32: tps5103-tps5103. DOI: 10.1200/jco.2014.32.15_suppl.tps5103.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply